Shilpa Medicare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Shilpa Medicare Ltd filed with BSE on 26 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Shilpa Medicare reported its highest ever quarterly revenue of Rs 439 crores in Q4 FY26, up 30% year-on-year, and full year FY26 revenue of Rs 1,549 crores, up 18%. EBITDA margin for the year improved to 29%, with management attributing the gains to increased revenue from key verticals driving operating leverage. Management described progress across API, formulations, biologics and CDMO programs, including new product launches, regulatory submissions, and capacity additions planned for FY27 and beyond.
Numbers mentioned
Revenue: INR439 crores (Q4 FY26)
p. 6
“I'm pleased to report that we have delivered our highest ever quarterly revenues of INR439 crores, recording a growth of 30% year-on-year.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Revenue: INR1,549 crores (FY26)
p. 6
“And for the full year '26, we have had historic revenue number, delivering INR1,549 crores, growing at 18%.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Gross margin: 68% for quarter, 70% for full year (Q4 FY26 / FY26)
p. 6
“Our gross margin continued to remain healthy at 68% for the quarter and 70% for the full year.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
EBITDA: INR121 crores (Q4 FY26)
p. 6
“For the quarter, EBITDA was at INR121 crores, growing at 40% year-on-year with an EBITDA margin of 28%, improving around 2% year-on-year”
Alpesh Dalal, page 6 of the filed PDF · View the filing
EBITDA: INR445 crores (FY26)
p. 6
“whereas for the full year, EBITDA was at INR445 crores, reflecting a growth of 30% year-on-year, with yearly EBITDA margin of 29%, an, ~3% year-on-year improvement.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Exceptional gain: INR30 crores (Q4 FY26)
p. 6
“During the quarter, we also had an exceptional gain amounting to INR30 crores on account of stake sale in one of our JV company, Sravathi Advance, where we have sold 31% stake and now hold 34% stake.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Adjusted PAT: INR87 crores (Q4 FY26)
p. 6
“Overall, our adjusted PAT before considering any exceptional gain for the quarter was INR87 crores.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Adjusted PAT: INR232 crores (FY26)
p. 6
“And for the full year, it was INR232 crores, growing at about 135% year-on-year.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Net debt: INR613 crores (FY26)
p. 6
“On the debt front, our net debt for the year increased to INR613 crores from INR550 crores in the previous year, which is in line with the growth in our business operations.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Capex: INR361 crores (FY26)
p. 6
“And our capex of INR361 crores in FY26 was primarily funded by internal accruals and deployed in key verticals of API, CDMO and albumin facility.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Adjusted ROCE: 17.4% (FY26)
p. 6
“our adjusted ROCE, excluding investments made in high-growth potential businesses like biologics and albumin, has seen a significant improvement from 4% in FY23 to 17.4% in FY26.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
API segment revenue: INR259 crores (quarter), INR985 crores (full year) (Q4 FY26 / FY26)
p. 6
“Our API business clocked a revenue of INR259 crores for the quarter and INR985 crores for the full year, growing at 16%, both on a quarterly as well as yearly basis.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
Formulation segment revenue: INR205 crores (quarter), INR618 crores (full year) (Q4 FY26 / FY26)
p. 6
“Formulation revenue for the quarter were INR205 crores, growing at 54% year-on-year, and revenue for the full year were INR618 crores, growing at 30% year-on-year.”
Alpesh Dalal, page 6 of the filed PDF · View the filing
European formulation revenue: over INR200 crores (FY26)
p. 7
“our strategy of developing and launching niche products globally through strategic partners is gaining very good traction, as evidenced by our European formulation business, which delivered revenues of over INR200 crores, growing by more than 100% yearon-year.”
Alpesh Dalal, page 7 of the filed PDF · View the filing
Biologics segment revenue: INR150 crores (FY26)
p. 7
“Moving to the Biologics segment. The revenue for the year were INR150 crores, growing roughly 100% year-on-year.”
Alpesh Dalal, page 7 of the filed PDF · View the filing
CDMO business (API): approximately INR110 crores (FY26)
p. 17
“For the full year on the API side of the business, we have clocked approximately around INR110 crores of CDMO business.”
Keshav Bhutada, page 17 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Unicycive Therapeutics API/formulation program approval — FY27 approval · FY27
stated firmly by Keshav Bhutada
p. 3
“The program submissions are already done, and we are expecting approval in this financial year FY27.”
Keshav Bhutada, page 3 of the filed PDF · View the filing
OLC block validation batches — Q1 FY27
stated firmly by Keshav Bhutada
p. 4
“And we are planning to do the validation batches in this new block in Q1 FY27.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
New oncology block commissioning — FY27
stated firmly by Keshav Bhutada
p. 4
“The block is expected to get commissioned in FY27.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
Peptide manufacturing block commissioning — FY27
stated firmly by Keshav Bhutada
p. 4
“New dedicated peptide large-scale manufacturing block, the equipment ordering is already completed, and we are expecting to commission the facility in FY27.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
API business growth — steady growth · FY27
stated as an aspiration by Keshav Bhutada
p. 4
“Overall, API business is likely to have a steady growth in next financial year FY27.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
Enzalutamide and Abraxane commercialization — FY28
stated firmly by Keshav Bhutada
p. 4
“So, both Abraxane and Enzalutamide tablets are expected to get commercialized in FY28.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
Rotigotine Transdermal Patch Europe launch — FY27
stated firmly by Keshav Bhutada
p. 4
“Rotigotine Transdermal Patch Europe launch, as explained in the previous call, will be launched in Europe in FY27.”
Keshav Bhutada, page 4 of the filed PDF · View the filing
Ondansetron extended-release injection India launch — FY27
stated firmly by Keshav Bhutada
p. 5
“Ondansetron extended-release injection, which is one of a very complex injectable product developed by us, we are expecting to launch in FY27 in India.”
Keshav Bhutada, page 5 of the filed PDF · View the filing
Aflibercept launch — FY27
stated firmly by Keshav Bhutada
p. 5
“Aflibercept, which is one of our most complex ophthalmic product, our human clinical study is on-going, and we are on track for launch for FY27.”
Keshav Bhutada, page 5 of the filed PDF · View the filing
IMPD submission for albumin Europe study — H1 FY27
stated firmly by Keshav Bhutada
p. 5
“That submission is planned in first half of FY27.”
Keshav Bhutada, page 5 of the filed PDF · View the filing
Formulation division growth — good growth possibility · FY27
stated as an aspiration by Keshav Bhutada
p. 5
“Overall, with existing and new product launches, there is likely to be a good growth possibility in FY27 in the formulation division.”
Keshav Bhutada, page 5 of the filed PDF · View the filing
EBITDA margin — 35% · next 1 to 2 years
stated as an aspiration by Alpesh Dalal
p. 8
“But obviously 35% is an ambitious target, which we would be working towards achieving.”
Alpesh Dalal, page 8 of the filed PDF · View the filing
Licensing income — similar range · FY27
stated conditionally by Alpesh Dalal
p. 8
“So it will depend on some of those aspects. But generally, we do expect our licensing revenue to remain in similar range at least.”
Alpesh Dalal, page 8 of the filed PDF · View the filing
European formulation business growth — healthy growth · FY27
stated as an aspiration by Alpesh Dalal
p. 9
“We may not be in a position to provide any guidance, but we do expect the European business to have a healthy growth.”
Alpesh Dalal, page 9 of the filed PDF · View the filing
Nilotinib Europe volume impact — FY28
stated conditionally by Keshav Bhutada
p. 8
“So we don't see that for the current financial year, there will be a significant change in the Nilotinib volumes with respect to value. The more impact will be there for the FY28.”
Keshav Bhutada, page 8 of the filed PDF · View the filing
Tadalafil oral disintegrating film Europe launch — FY27
stated firmly by Keshav Bhutada
p. 9
“we have Tadalafil oral disintegrating film that will be launched in Europe in this financial year.”
Keshav Bhutada, page 9 of the filed PDF · View the filing
OLC contribution to revenue — no meaningful contribution · FY27
stated firmly by Keshav Bhutada
p. 10
“We don’t project any meaningful contribution coming from OLC in FY27.”
Keshav Bhutada, page 10 of the filed PDF · View the filing
Biologics/ADC/NBE global human studies entry — current financial year
stated firmly by Keshav Bhutada
p. 11
“I think in the current financial year, Nivolumab. ADC product and 2 NBE products, will be entering human global studies in current financial year.”
Keshav Bhutada, page 11 of the filed PDF · View the filing
Nivolumab/Adalimumab Europe and ROW commercial revenues — FY29
stated firmly by Keshav Bhutada
p. 11
“We expect sometime in FY29, the commercial revenues to start in from Europe and ROW.”
Keshav Bhutada, page 11 of the filed PDF · View the filing
NorUDCA ROW market revenues — FY28
stated firmly by Keshav Bhutada
p. 11
“Even NorUDCA would be in FY29 for Europe, but if I tell you about ROW market, we will start seeing revenues in FY28 in ROW markets.”
Keshav Bhutada, page 11 of the filed PDF · View the filing
Dutasteride global human studies — current financial year
stated firmly by Keshav Bhutada
p. 12
“And now we are entering into global studies. So that is what we will be starting in the current financial year.”
Keshav Bhutada, page 12 of the filed PDF · View the filing
Capex growth — no significant growth over last year
stated firmly by Keshav Bhutada
p. 16
“Like for the current year already, it's available. So we don't see any significant capex growth than last year. It will continue to sustain.”
Keshav Bhutada, page 16 of the filed PDF · View the filing
Oncology breakthrough molecule for innovator — meaningful contribution · FY28
stated firmly by Keshav Bhutada
p. 17
“Yes, we expect it should be meaningful in FY28.”
Keshav Bhutada, page 17 of the filed PDF · View the filing
Rotigotine patch ramp-up — full potential · FY28
stated firmly by Keshav Bhutada
p. 16
“So in the current year, it will be more like initial launch and ramp up will happen in the subsequent which is FY28.”
Keshav Bhutada, page 16 of the filed PDF · View the filing
Nilotinib rest-of-world launches — next financial year
stated firmly by Keshav Bhutada
p. 17
“And we will be launching in some of the rest of the world markets also in next financial year.”
Keshav Bhutada, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said US revenue has increased and will likely continue, but they stopped selling generic azacitidine due to changed market dynamics and are now focusing on super specialty products.
Answered by Keshav Bhutada
Asked by Kiran D.: Why hasn't US formulation revenue grown steeply despite the US partner's market share gains?
p. 7
“So now we are focusing more on selling super specialty products.”
Keshav Bhutada, page 7 of the filed PDF · View the filing
Management said they need to observe the full 6-month disease treatment cycle before commenting further, with better visibility expected in Q2.
Answered by Keshav Bhutada
Asked by Kiran D.: Will NorUDCA see a steep scale-up in FY27?
p. 8
“So we must observe how the volumes will further grow. So we will be able to give you a clearer picture in sometimes in second quarter of this year.”
Keshav Bhutada, page 8 of the filed PDF · View the filing
CFO said 35% is an ambitious target being worked towards but cannot be achieved immediately given continued investment needs.
Answered by Alpesh Dalal
Asked by Kiran D.: Do you expect EBITDA margins to reach 35% in 1-2 years?
p. 8
“But we can't really say that it would be achieved immediately because whilst we grow the business, we also have to spend more for growing the business.”
Alpesh Dalal, page 8 of the filed PDF · View the filing
Management said CDMO will be the main growth driver in FY27, along with licensing income from biosimilars in Europe and ROW markets.
Answered by Keshav Bhutada
Asked by Ankit Gupta: What is driving growth in biologics for FY27 and FY28?
p. 9
“So for the current year, you will see mainly in biologics, the main growth drivers will be CDMO.”
Keshav Bhutada, page 9 of the filed PDF · View the filing
CFO explained this came from associate entity Maaia, which showed a significant performance improvement this year after previously reporting losses, but cautioned this may not be a regular recurring feature.
Answered by Alpesh Dalal
Asked by Krisha Kansara: What drove the INR18 crores share of profit from associates/JVs this quarter?
p. 10
“Whether it can continue with the same set of performance or not is very difficult for us to comment because that's not an entity that we control.”
Alpesh Dalal, page 10 of the filed PDF · View the filing
Management said the delay is because batches for IMPD submission are being made from the new facility and must be completed first.
Answered by Keshav Bhutada
Asked by Girish Bakhru: Why was the albumin IMPD submission delayed from Q4 to first half of FY27?
p. 13
“So in the new facility, the batches for IMPD submission are ongoing. So once that is complete, then we will be submitting.”
Keshav Bhutada, page 13 of the filed PDF · View the filing
Management said the FDA gave observations, compliance has been completed, and they are awaiting reaudit, with no expected revenue impact since most US products are made via third-party CMOs.
Answered by Keshav Bhutada
Asked by Abhishek: What is the status of the Jadcherla USFDA audit?
p. 16
“We have done the compliance. And now we are again waiting for the reaudit of that.”
Keshav Bhutada, page 16 of the filed PDF · View the filing
Management said CDMO revenue for the full year was approximately INR110 crores on the API side, with similar CDMO business also in biologics.
Answered by Keshav Bhutada
Asked by Vishal Manchanda: What was the total CDMO business across API, formulations and biologics?
p. 17
“And we are also doing similar CDMO business on the biologics side also. So majorly, our CDMO revenues are in API and biologics.”
Keshav Bhutada, page 17 of the filed PDF · View the filing
Risks flagged
Raw material and solvent prices have increased significantly
p. 15
“but only the prices have gone up significantly. So that is the only thing, but availability is there, no problem.”
Keshav Bhutada, page 15 of the filed PDF · View the filing
Aflibercept Europe study is costly and lengthy, and company feels it may be late to that market
p. 11
“there is no plan of going into Europe market because it's a very long study and very costly study, and we feel that we are late for Europe market.”
Keshav Bhutada, page 11 of the filed PDF · View the filing
Associate entity Maaia's continued performance improvement is uncertain since the company does not control it
p. 10
“Whether it can continue with the same set of performance or not is very difficult for us to comment because that's not an entity that we control.”
Alpesh Dalal, page 10 of the filed PDF · View the filing
US FDA facility audit resulted in observations still pending reaudit
p. 16
“It's just that the facility when the audit happened, the FDA has given some observations.”
Keshav Bhutada, page 16 of the filed PDF · View the filing
Some tentative approval products face late patent expiry limiting launch value
p. 16
“However, there are few products which are having high value and have tentative approval, but the patent expiry and the launch for those products are late.”
Keshav Bhutada, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.